Rossi Luiga, Serafini Sonja, Pierigé Francesca, Antonelli Antonella, Cerasi Aurora, Fraternale Alessandra, Chiarantini Laura, Magnani Mauro
Università degli Studi di Urbino Carlo Bo, Istituto di Chimica Biologica G Fornaini, Italy.
Expert Opin Drug Deliv. 2005 Mar;2(2):311-22. doi: 10.1517/17425247.2.2.311.
The use of a physiological carrier to deliver therapeutics throughout the body to both improve their efficacy while minimising inevitable adverse side effects, is an extremely fascinating perspective. The behaviour of erythrocytes as a delivery system for several classes of molecules (i.e., proteins, including enzymes and peptides, therapeutic agents in the form of nucleotide analogues, glucocorticoid analogues) has been studied extensively as they possess several properties, which make them unique and useful carriers. Furthermore, the possibility of using carrier erythrocytes for selective drug targeting to differentiated macrophages increases the opportunities to treat intracellular pathogens and to develop new drugs. Finally, the availability of an apparatus that permits the encapsulation of drugs into autologous erythrocytes has made this technology available in many clinical settings and competitive with other drug delivery systems.
利用生理载体将治疗药物输送至全身，既能提高疗效，又能将不可避免的不良副作用降至最低，这是一个极具吸引力的设想。红细胞作为几类分子（即蛋白质，包括酶和肽、核苷酸类似物形式的治疗剂、糖皮质激素类似物）的递送系统，因其具有多种特性而成为独特且有用的载体，人们对其行为进行了广泛研究。此外，使用载体红细胞对分化巨噬细胞进行选择性药物靶向的可能性增加了治疗细胞内病原体和开发新药的机会。最后，一种能够将药物封装到自体红细胞中的设备的出现，使得这项技术在许多临床环境中得以应用，并与其他药物递送系统形成竞争。
